ResMed (NYSE:RMD) Price Target Raised to $244.00 at Royal Bank Of Canada

ResMed (NYSE:RMD) had its target price increased by Royal Bank Of Canada from $234.00 to $244.00 in a research note published on Friday,Benzinga reports. The firm currently has a sector perform rating on the medical equipment provider’s stock.

A number of other equities research analysts also recently weighed in on the stock. Morgan Stanley reaffirmed an “equal weight” rating and set a $230.00 price objective (down from $286.00) on shares of ResMed in a research report on Wednesday, June 17th. Weiss Ratings lowered ResMed from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, July 24th. Mizuho dropped their price target on ResMed from $235.00 to $220.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. The Goldman Sachs Group restated a “buy” rating on shares of ResMed in a research report on Wednesday, July 1st. Finally, KeyCorp dropped their target price on ResMed from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday. Seven investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $240.17.

ResMed Price Performance

Shares of NYSE RMD opened at $211.84 on Friday. The company has a current ratio of 3.01, a quick ratio of 2.33 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $30.73 billion, a price-to-earnings ratio of 20.31, a price-to-earnings-growth ratio of 1.36 and a beta of 0.76. ResMed has a twelve month low of $180.26 and a twelve month high of $293.81. The business has a 50 day simple moving average of $200.49 and a 200-day simple moving average of $222.23.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.89 by $0.06. ResMed had a return on equity of 25.86% and a net margin of 26.94%.The firm had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.46 billion. During the same period last year, the business posted $2.55 earnings per share. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. As a group, equities research analysts expect that ResMed will post 12.02 earnings per share for the current year.

ResMed Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 24th. Shareholders of record on Thursday, August 20th will be paid a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Thursday, August 20th. This is an increase from ResMed’s previous quarterly dividend of $0.60. ResMed’s dividend payout ratio (DPR) is presently 23.14%.

Insiders Place Their Bets

In related news, Director Peter C. Farrell sold 8,000 shares of ResMed stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $225.00, for a total transaction of $1,800,000.00. Following the sale, the director directly owned 52,773 shares in the company, valued at $11,873,925. The trade was a 13.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael J. Farrell sold 4,991 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $218.55, for a total transaction of $1,090,783.05. Following the completion of the sale, the chief executive officer directly owned 466,223 shares of the company’s stock, valued at $101,893,036.65. The trade was a 1.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 17,982 shares of company stock valued at $3,858,837 in the last quarter. 0.65% of the stock is currently owned by insiders.

Institutional Trading of ResMed

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Imprint Wealth LLC acquired a new position in shares of ResMed during the third quarter valued at approximately $26,000. WFA of San Diego LLC acquired a new stake in ResMed in the second quarter worth approximately $26,000. International Assets Investment Management LLC bought a new position in ResMed during the 4th quarter valued at $25,000. Sunbelt Securities Inc. acquired a new position in shares of ResMed during the 3rd quarter valued at $31,000. Finally, Bell Investment Advisors Inc acquired a new position in shares of ResMed during the 2nd quarter valued at $26,000. 54.98% of the stock is currently owned by institutional investors.

Key Stories Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: ResMed reported fiscal Q4 earnings of $2.95 per share, beating the approximately $2.89–$2.90 consensus and rising from $2.55 a year earlier. Revenue increased 8.6% year over year to $1.46 billion, in line with estimates. ResMed Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: The company raised its quarterly dividend from $0.60 to $0.66 per share, a 10% increase. The dividend is payable September 24 to shareholders of record on August 20, supporting ResMed’s income-investment appeal. ResMed Posts Strong Q4 Earnings and Lifts Dividend
• Positive Sentiment: Royal Bank of Canada raised its price target to $244 from $234 while retaining a “sector perform” rating, indicating potential upside from recent trading levels. Benzinga analyst action
• Neutral Sentiment: Analyst sentiment remains mixed. Piper Sandler lowered its target to $225 and Wells Fargo cut its target to $215; both maintain neutral or equal-weight ratings. The overall analyst consensus remains “Hold,” despite a consensus target near $246. ResMed Analyst Ratings
• Negative Sentiment: The primary pressure on RMD is forward guidance: fiscal 2027 revenue expectations reportedly trail consensus, raising concerns that growth may moderate even after the quarterly earnings beat. RMD Stock Down Despite Q4 Earnings Beat
• Negative Sentiment: Director Peter Farrell sold 8,000 shares worth $1.8 million. The sale was made under a pre-arranged Rule 10b5-1 plan, reducing its negative signaling value, but it may add modest short-term selling pressure. SEC Insider Trading Filing

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.